Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Korea United PharmXKRX:033270 -1.38%90 Operating Margin % is 17.62% as of Jun. 2026, which is 5% above its 10-year median of 16.73. GuruFocus rates XKRX:033270 with a GF Score™ of 90/100 and a GF Value™ of ₩20,354.74 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 957 Drug Manufacturers companies, Korea United Pharm ranks better than 90.8% on this metric.
Korea United Pharm Inc operating margin has been in a 5-year decline. The average rate of decline per year is -2.9%.
The historical rank and industry rank for Korea United Pharm's Operating Margin % or its related term are showing as below:
XKRX:033270'
s Operating Margin % Range Over the Past 10 Years
Min: 11.61 Med: 16.73 Max: 19.82
Current: 16.82
XKRX:033270's Operating Margin % is ranked better than 90.8% of 957
companies
in the Drug Manufacturers industry
Industry Median: 7.96
vs XKRX:033270: 16.82
Korea United Pharm's 5-Year Average Operating Margin % Growth Rate was -2.90% per year.
Korea United Pharm (XKRX:033270) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Korea United Pharm Operating Margin % Related Terms
Korea United Pharm Operating Margin % Historical Data
* Premium members only.
The historical data trend for Korea United Pharm's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Korea United Pharm's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Korea United Pharm Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Korea United Pharm's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Korea United Pharm's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Korea United Pharm's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Korea United Pharm (XKRX:033270) has a Operating Margin % of 17.62% as of Jun. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Korea United Pharm and its competitors. This is near median its historical median of 16.73. Over the past decade, Korea United Pharm's Operating Margin % has ranged from 11.61 to 19.82. According to the industry distribution chart, Korea United Pharm ranks #88 out of 957 companies in the Drug Manufacturers industry, placing it in the top 9.2%.
Is Korea United Pharm's Operating Margin % too high?
Korea United Pharm's current Operating Margin % of 17.62% is near median its 10-year median of 16.73. Over the past 10 years, this metric has ranged from a low of 11.61 to a high of 19.82. The Drug Manufacturers industry median Operating Margin % is 7.96. Korea United Pharm's value of 17.62% is 121.4% above this industry median. Based on the distribution chart, Korea United Pharm ranks #88 out of 957 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Korea United Pharm has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Korea United Pharm's Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Korea United Pharm ranks #88 out of 957 companies for Operating Margin %. This places Korea United Pharm in the top 9% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.96. Korea United Pharm's value of 17.62% is 121.4% above this benchmark. Historically, Korea United Pharm's own Operating Margin % has ranged from 11.61 to 19.82 over the past decade. While the company's 10-year median is 16.73 vs. the industry median of 7.96, Korea United Pharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.96, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Korea United Pharm's current Operating Margin % of 17.62% is 121.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Korea United Pharm and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Korea United Pharm's current Operating Margin % is 17.62%, which is near median its own 10-year median of 16.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Korea United Pharm stock overvalued right now?
Based on GuruFocus' analysis, Korea United Pharm (XKRX:033270) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩20,354.74, compared to a current price of ₩17,910.00 — trading 12% below its estimated fair value. The current Operating Margin % is 17.62%, which is near median its 10-year median of 16.73 and 121.4% above the Drug Manufacturers industry median of 7.96. Korea United Pharm's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Korea United Pharm (XKRX:033270), the current Operating Margin % is 17.62% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Korea United Pharm (XKRX:033270) Overvalued in 2026?
Based on GuruFocus' analysis, Korea United Pharm stock appears to be undervalued.
The current stock price of ₩17,910.00 is trading 12% below its estimated GF Value™ of ₩20,354.74.
GuruFocus considers Korea United Pharm to be Modestly Undervalued.
Key valuation signals for XKRX:033270:
Operating Margin %: 17.62% (near median its 10-year median of 16.73)
GF Value™: ₩20,354.74 vs. price of ₩17,910.00 (12% below fair value)
Industry Position: 121.4% above the Drug Manufacturers median (#88 of 957)
No single metric tells the full story. See the XKRX:033270 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Korea United Pharm Inc is a South Korea based company engages in the manufacture and distribution of pharmaceuticals and healthcare products. It offers incrementally modified drug, anti-cancer, prescription, and OTC products.
90GF Score
Get the complete analysis for XKRX:033270
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:033270 has been successfully added to your 
